This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n17http://localhost/temp/predkladatel/
n18http://linked.opendata.cz/resource/domain/vavai/projekt/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n3http://linked.opendata.cz/ontology/domain/vavai/
n6http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F09%3A00002259%21RIV11-MSM-11120___/
n14http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n13http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F09%3A00002259%21RIV11-MSM-11120___
rdf:type
n3:Vysledek skos:Concept
dcterms:description
Objectives: We sought to identify factors that discriminate heart failure (HF) patients with normal and elevated pulmonary vascular resistance (PVR) and to elucidate the role of cyclic guanosine monophosphate (cGMP)-dependent vasodilation. Background: Mechanisms of PVR increase in patients with chronic HF are incompletely understood. Methods: Twenty-two HF patients with high pulmonary vascular resistance (H-PVR) (>200 dyn.s.cm(-5)) were compared with 24 matched low pulmonary vascular resistance (L-PVR) patients of similar age, sex, body size, HF severity, and volume status who were undergoing invasive hemodynamic study. Pulmonary arterial (PA) and venous blood samples from a wedged PA catheter were used to calculate transpulmonary B-type natriuretic peptide (BNP) uptake and cGMP release. The H-PVR patients were re-examined 1 h after a 40-mg oral dose of sildenafil Objectives: We sought to identify factors that discriminate heart failure (HF) patients with normal and elevated pulmonary vascular resistance (PVR) and to elucidate the role of cyclic guanosine monophosphate (cGMP)-dependent vasodilation. Background: Mechanisms of PVR increase in patients with chronic HF are incompletely understood. Methods: Twenty-two HF patients with high pulmonary vascular resistance (H-PVR) (>200 dyn.s.cm(-5)) were compared with 24 matched low pulmonary vascular resistance (L-PVR) patients of similar age, sex, body size, HF severity, and volume status who were undergoing invasive hemodynamic study. Pulmonary arterial (PA) and venous blood samples from a wedged PA catheter were used to calculate transpulmonary B-type natriuretic peptide (BNP) uptake and cGMP release. The H-PVR patients were re-examined 1 h after a 40-mg oral dose of sildenafil
dcterms:title
Transpulmonary B-Type Natriuretic Peptide Uptake and Cyclic Guanosine Monophosphate Release in Heart Failure and Pulmonary Hypertension The Effects of Sildenafil Transpulmonary B-Type Natriuretic Peptide Uptake and Cyclic Guanosine Monophosphate Release in Heart Failure and Pulmonary Hypertension The Effects of Sildenafil
skos:prefLabel
Transpulmonary B-Type Natriuretic Peptide Uptake and Cyclic Guanosine Monophosphate Release in Heart Failure and Pulmonary Hypertension The Effects of Sildenafil Transpulmonary B-Type Natriuretic Peptide Uptake and Cyclic Guanosine Monophosphate Release in Heart Failure and Pulmonary Hypertension The Effects of Sildenafil
skos:notation
RIV/00216208:11120/09:00002259!RIV11-MSM-11120___
n4:aktivita
n8:S n8:P n8:Z
n4:aktivity
P(1M0510), P(GA305/09/1390), S, Z(MZ0IKEM2005)
n4:cisloPeriodika
7
n4:dodaniDat
n13:2011
n4:domaciTvurceVysledku
n5:5053587 n5:1236105
n4:druhVysledku
n10:J
n4:duvernostUdaju
n15:S
n4:entitaPredkladatele
n6:predkladatel
n4:idSjednocenehoVysledku
346829
n4:idVysledku
RIV/00216208:11120/09:00002259
n4:jazykVysledku
n19:eng
n4:klicovaSlova
heart failure; pulmonary vascular resistance; cGMP; sildenafil; pulmonary hypertension
n4:klicoveSlovo
n7:sildenafil n7:heart%20failure n7:pulmonary%20vascular%20resistance n7:cGMP n7:pulmonary%20hypertension
n4:kodStatuVydavatele
NL - Nizozemsko
n4:kontrolniKodProRIV
[88796023FEAF]
n4:nazevZdroje
Journal of the American College of Cardiology
n4:obor
n9:FA
n4:pocetDomacichTvurcuVysledku
2
n4:pocetTvurcuVysledku
8
n4:projekt
n18:GA305%2F09%2F1390 n18:1M0510
n4:rokUplatneniVysledku
n13:2009
n4:svazekPeriodika
54
n4:tvurceVysledku
Melenovský, V. Jabor, Antonín Syrovátka, Petr
n4:wos
000268761100002
n4:zamer
n14:MZ0IKEM2005
s:issn
0735-1097
s:numberOfPages
6
n17:organizacniJednotka
11120